The Phase I trial, which is being conducted in the US, is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TC-5214 in healthy volunteers. TC-5214 is the S(+) enantiomer of the racemate mecamylamine hydrochloride, a broad spectrum NNR antagonist.
In preclinical studies, TC-5214 has exhibited a better overall safety and efficacy profile than mecamylamine. A Phase II clinical proof of concept trial is planned for later in 2008.
Donald deBethizy, president and CEO of Targacept, said: “We are delighted by the entry of TC-5214 into the clinic and enthusiastic about its strong therapeutic potential. The NNR mechanism represents an exciting new paradigm in the development of treatments for depression, a particularly critical health issue that demands a novel therapeutic approach.”